• Users Online: 161
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 2  |  Issue : 2  |  Page : 75-79

EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious

1 Department of Medicine, KPC Medical College and Hospital, Kolkata, West Bengal, India
2 Department of Medical Affairs, Boehringer Ingelheim Pvt. Ltd., Mumbai, Maharashtra, India

Correspondence Address:
Dr. Rishad Ahmed
26 Shamsul Huda Road, 3rd Floor, Kolkata - 700 017, West Bengal
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/bjhs.bjhs_19_17

Rights and Permissions

With the addition of sodium–glucose cotransporter-2 inhibitors to the current arsenal of oral antidiabetics (OAD), a lot has changed. From questioning their glucouretic mechanism to understanding their pleiotropic effects, it has been an eventful journey. In 2008, after the rosiglitazone fiasco, the US Food and Drug Administration (FDA) mandate was passed to ensure the safety of the OAD. Up to the gliptins, there was an era of cardiovascular (CV) safety which progressed to CV protection with the EMPA-REG OUTCOME trial. It came with a lot of questions regarding the probable mechanism and the doubts of whether it will translate into a class effect or not. After the Canagliflozin CV Assessment Study results, a lot of things have come into light regarding the overall benefits with these molecules. This review highlights the similarities and dissimilarities in the two trial results.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded420    
    Comments [Add]    

Recommend this journal